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Peripheral corneal melting syndrome is a rare immune condition characterized by marginal
corneal thinning and sometimes perforation. It is associated with rheumatic and non-
rheumatic diseases. Few cases of peripheral corneal melting have been reported in patients
with psoriasis. The pathogenesis is not fully understood but metalloproteinases may play
a  pathogenic role. Anti-TNF therapy has shown to decrease skin and serum metallopro-
teinases levels in psoriasis. We  report a 61-year-old man with peripheral corneal melting
syndrome associated with psoriatic arthritis who received adalimumab to control skin and
ocular  inﬂammation. To our knowledge, this is the ﬁrst case report of peripheral corneal
melting syndrome in psoriatic arthritis treated with adalimumab showing resolution of skin
lesions and complete healing of corneal perforation in three months.
© 2014 Elsevier Editora Ltda. All rights reserved.
Síndrome  da  ceratomalácia  (Corneal  Melting)  periférica  na  artrite
psoriásica  tratada  com  adalimumabe
alavras-chave:
erfurac¸ão da córnea
rtrite psoriásica
dalimumabe
r  e  s  u  m  o
A síndrome do corneal melting periférica é uma rara condic¸ão imune caracterizada por aﬁ-
namento da margem da córnea e, às vezes, perfurac¸ão. Está associada a doenc¸as reumáticas
e  não reumáticas. Poucos casos de síndrome do corneal melting periférica foram relata-
dos  em pacientes com psoríase. A patogênese não foi completamente entendida, mas  asmetaloproteinases podem ter papel patogênico. A terapia Anti-TNF diminuiu os níveis de
a pele e no sangue em psoríase. Reportamos o caso de um homem demetaloproteinases n61  anos com síndrome do corneal melting periférica associada à artrite psoriásica que rece-
beu  adalimumabe para controlar a inﬂamac¸ão na pele e no olho. Pelo que sabemos, este é o
primeiro caso de síndrome do corneal melting periférica em artrite psoriática tratado com
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adalimumabe mostrando evoluc¸ão nas lesões cutâneas e cura total da perfurac¸ão da córnea
em  três meses.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Peripheral corneal melting syndrome (PCMS) is a rare immune
condition characterized by marginal corneal thinning and
sometimes perforation. It is associated with rheumatic
and non-rheumatic diseases. The list includes rheumatoid
arthritis, Sjogren’s syndrome, systemic lupus erythematosus,
Wegener’s granulomatosis, microscopic polyangiitis, topical
non-steroidal anti-inﬂammatory drugs, pregnancy and psori-
asis. Ocular manifestations of psoriasis are rare and extensive.
Psoriasis can affect the lids, conjunctiva, cornea and anterior
uveal tract. The pathogenesis of PCMS is not fully understood,
but metalloproteinases may play a pathogenic role. Anti-TNF
therapy has shown to decrease skin and serum metallopro-
teinases levels in psoriasis and psoriatic arthritis. We report
a 61-year-old man  with peripheral corneal melting syndrome
associated with psoriasis who received adalimumab to con-
trol skin and ocular inﬂammation. Since we  know this is the
ﬁrst case report of PCMS in psoriatic arthritis treated with
adalimumab.
Case  report
A 61-year-old man  was referred to our rheumatology service in
October 2010 with a four-month history of left blurred vision,
photophobia and painful red eye. He had a 6-year chronic
plaque psoriasis with arthritis and uveitis.
An ophtalmologic examination revealed a left inferior
paracentral perforation. Schirmer’s test was 5 mm/5  min  and
slit-lamp examination did not show cells in the anterior cham-
ber. Due to the severity of the case he was managed with
cyanoacrylate glue (Fig. 1) and topical atropine, prednisone
plus phenylephrine, carboxymethylcellulose, ciproﬂoxacine.
Fig. 1 – Left inferior paracentral perforation occluded with
cyanoacrylate glue.Rheumatology evaluation showed swan-neck ﬁngers with
ulnar deviation and irreversible limitation in range of motion
without inﬂammatory signs. The physical examination also
revealed extense plaques of psoriasis involving the trunk,
upper and lower limbs.
Blood count, glucose, liver function tests, CRP were normal,
creatinine was 1.44 mg/dL (<1 mg/dL) with blood urea nitrogen:
8.3 mg/dL, and erythrocyte sedimentation rate was 32 mm/h.
Rheumatoid factor, anti-CCP, antinuclear antibodies, anti-Ro,
anti-La, anti-SM, anti-RNP, HLA-B27 were negative. The hands
radiography showed the typical pencil-in-cup deformity.
Two weeks after PCMS occurred we started adalimumab
80 mg followed by 40 mg  every other week administered sub-
cutaneously with resolution of skin lesions and complete
healing of corneal perforation in 3 months (Fig. 2).
Discussion
Corneal melting syndrome is a rare disease consisting of
corneal thinning with ulceration that sometimes leads to
perforation.1 It is most commonly associated with rheuma-
toid arthritis, followed by Wegener’s granulomatosis and
microscopic polyangiitis respectively.2 Other causes include
Sjogren’s syndrome,3 systemic lupus erythematosus,4 topical
non-steroidal anti-inﬂammatory drugs,5 pregnancy,6 pol-
yarteritis nodosa and psoriasis.7
Psoriasis affects nearly every layer of the eye in approx-
imately 10% of the cases. Ophalmologic features consist of
corneal opacities, conjunctivitis, superﬁcial keratitis, chronic
iridocyclitis, uveitis and dry eyes.8 PCMS begins with ulcer-
ation and melting of the cornea; without a prompt and
appropriated treatment the patient could experience a perfo-
ration and ﬁnally the loss of vision and integrity of the globe.
The disease may be classiﬁed by anatomical location: central
Fig. 2 – Cyanoacrylate glue degradation after complete
healing of corneal perforation.
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Table 1 – Summary of four cases of PCMS associated with psoriasis.1,8
Case Gender Age Location Perforation arthritis Psoriasis type
1 Female 62 Peripheral + Pustular
2 Male 70 Peripheral − Plaques
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12. Chan S, Boisjoly H. Advances in the use of adhesives in
ophthalmology. Curr Opin Ophthalmol. 2004;15:3 Female 83 Pe
4 Male 61 Pe
nd peripheral or by pathogenic mechanism: inﬂammatory
nd non-inﬂammatory. Four cases including ours have been
eported (Table 1).
The pathogenesis of PCMS is still unclear. PCMS can be
nitiated by local factors including ophthalmic vasculitis,
cular surface disease like corneal infection and sicca syn-
rome. Increased levels of matrix metalloproteinases 1, 2,
, 9 in melted corneal specimens have been found.9 The
roduction of metalloproteinases can degradate basal mem-
rane components of the cornea leading to ulceration and
nally perforation. It is rational the treatment with adali-
umab since anti-TNF therapy has demonstrated to decrease
he expression of metalloproteinases in skin and serum of
atients with psoriasis and psoriatic arthritis.10,11 Local treat-
ent of PCMS consists in the use of cyanoacrylate glue
hich can effectively seal small corneal (<3 mm diameter) and
ncomplicated perforations and the mean duration for glue
n situ was 45–72 days.12
Finally, we believe that despite PCMS in psoriasis and
soriatic arthritis is rare, the role of metalloproteinases in
orneal destruction suggests that this complication during the
ourse of psoriatic arthritis could be a causal association. More
esearch is needed to determine whether the use of anti-TNF
herapy could be useful in accelerating corneal healing PCMS
n psoriatic arthritis.
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